Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Identifieur interne : 000227 ( PubMed/Corpus ); précédent : 000226; suivant : 000228Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Auteurs : Felicia T. Roncolato ; Dominique Berton-Rigaud ; Rachel O'Connell ; Anne Lanceley ; Jalid Sehouli ; Luke Buizen ; Aikou Okamoto ; Eriko Aotani ; Domenica Lorusso ; Paul Donnellan ; Amit Oza ; Elisabeth Avall-Lundqvist ; Jonathan Berek ; Felix Hilpert ; Jonathan A. Ledermann ; Marie Christine Kaminsky ; Martin R. Stockler ; Madeleine T. King ; Michael FriedlanderSource :
- Gynecologic oncology [ 1095-6859 ] ; 2017.
Abstract
Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).
DOI: 10.1016/j.ygyno.2017.10.019
PubMed: 29107348
Links to Exploration step
pubmed:29107348Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).</title><author><name sortKey="Roncolato, Felicia T" sort="Roncolato, Felicia T" uniqKey="Roncolato F" first="Felicia T" last="Roncolato">Felicia T. Roncolato</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia. Electronic address: felicia.roncolato@ctc.usyd.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Berton Rigaud, Dominique" sort="Berton Rigaud, Dominique" uniqKey="Berton Rigaud D" first="Dominique" last="Berton-Rigaud">Dominique Berton-Rigaud</name><affiliation><nlm:affiliation>ICO Centre René Gauducheau, Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="O Connell, Rachel" sort="O Connell, Rachel" uniqKey="O Connell R" first="Rachel" last="O'Connell">Rachel O'Connell</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lanceley, Anne" sort="Lanceley, Anne" uniqKey="Lanceley A" first="Anne" last="Lanceley">Anne Lanceley</name><affiliation><nlm:affiliation>University College London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Sehouli, Jalid" sort="Sehouli, Jalid" uniqKey="Sehouli J" first="Jalid" last="Sehouli">Jalid Sehouli</name><affiliation><nlm:affiliation>Charite Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Buizen, Luke" sort="Buizen, Luke" uniqKey="Buizen L" first="Luke" last="Buizen">Luke Buizen</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Okamoto, Aikou" sort="Okamoto, Aikou" uniqKey="Okamoto A" first="Aikou" last="Okamoto">Aikou Okamoto</name><affiliation><nlm:affiliation>Jikei University School of Medicine, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Aotani, Eriko" sort="Aotani, Eriko" uniqKey="Aotani E" first="Eriko" last="Aotani">Eriko Aotani</name><affiliation><nlm:affiliation>Kitasato Academic Research Organization, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name><affiliation><nlm:affiliation>MITO, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Donnellan, Paul" sort="Donnellan, Paul" uniqKey="Donnellan P" first="Paul" last="Donnellan">Paul Donnellan</name><affiliation><nlm:affiliation>Galway University Hospital, Ireland; All-Ireland Oncology Research Group (ICORG), Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Oza, Amit" sort="Oza, Amit" uniqKey="Oza A" first="Amit" last="Oza">Amit Oza</name><affiliation><nlm:affiliation>Princess Margaret Hospital, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Avall Lundqvist, Elisabeth" sort="Avall Lundqvist, Elisabeth" uniqKey="Avall Lundqvist E" first="Elisabeth" last="Avall-Lundqvist">Elisabeth Avall-Lundqvist</name><affiliation><nlm:affiliation>Department of Oncology, Department of Clinical and Experimental Medicine, Linkoping, Sweden, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Berek, Jonathan" sort="Berek, Jonathan" uniqKey="Berek J" first="Jonathan" last="Berek">Jonathan Berek</name><affiliation><nlm:affiliation>Stanford Women's Cancer Center, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation><nlm:affiliation>Klinik fur Gynakologie und Geburtshilfe, UKSH, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ledermann, Jonathan A" sort="Ledermann, Jonathan A" uniqKey="Ledermann J" first="Jonathan A" last="Ledermann">Jonathan A. Ledermann</name><affiliation><nlm:affiliation>CRUK and UCL Cancer Trials Centre, NCRI UK, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Kaminsky, Marie Christine" sort="Kaminsky, Marie Christine" uniqKey="Kaminsky M" first="Marie Christine" last="Kaminsky">Marie Christine Kaminsky</name><affiliation><nlm:affiliation>ICL Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stockler, Martin R" sort="Stockler, Martin R" uniqKey="Stockler M" first="Martin R" last="Stockler">Martin R. Stockler</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="King, Madeleine T" sort="King, Madeleine T" uniqKey="King M" first="Madeleine T" last="King">Madeleine T. King</name><affiliation><nlm:affiliation>Psycho-oncology Research Group (PoCoG), School of Psychology, Central Clinical School, Sydney Medical School, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation><nlm:affiliation>Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29107348</idno><idno type="pmid">29107348</idno><idno type="doi">10.1016/j.ygyno.2017.10.019</idno><idno type="wicri:Area/PubMed/Corpus">000227</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000227</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).</title><author><name sortKey="Roncolato, Felicia T" sort="Roncolato, Felicia T" uniqKey="Roncolato F" first="Felicia T" last="Roncolato">Felicia T. Roncolato</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia. Electronic address: felicia.roncolato@ctc.usyd.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Berton Rigaud, Dominique" sort="Berton Rigaud, Dominique" uniqKey="Berton Rigaud D" first="Dominique" last="Berton-Rigaud">Dominique Berton-Rigaud</name><affiliation><nlm:affiliation>ICO Centre René Gauducheau, Saint Herblain, France.</nlm:affiliation></affiliation></author><author><name sortKey="O Connell, Rachel" sort="O Connell, Rachel" uniqKey="O Connell R" first="Rachel" last="O'Connell">Rachel O'Connell</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Lanceley, Anne" sort="Lanceley, Anne" uniqKey="Lanceley A" first="Anne" last="Lanceley">Anne Lanceley</name><affiliation><nlm:affiliation>University College London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Sehouli, Jalid" sort="Sehouli, Jalid" uniqKey="Sehouli J" first="Jalid" last="Sehouli">Jalid Sehouli</name><affiliation><nlm:affiliation>Charite Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Buizen, Luke" sort="Buizen, Luke" uniqKey="Buizen L" first="Luke" last="Buizen">Luke Buizen</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Okamoto, Aikou" sort="Okamoto, Aikou" uniqKey="Okamoto A" first="Aikou" last="Okamoto">Aikou Okamoto</name><affiliation><nlm:affiliation>Jikei University School of Medicine, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Aotani, Eriko" sort="Aotani, Eriko" uniqKey="Aotani E" first="Eriko" last="Aotani">Eriko Aotani</name><affiliation><nlm:affiliation>Kitasato Academic Research Organization, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Lorusso, Domenica" sort="Lorusso, Domenica" uniqKey="Lorusso D" first="Domenica" last="Lorusso">Domenica Lorusso</name><affiliation><nlm:affiliation>MITO, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Donnellan, Paul" sort="Donnellan, Paul" uniqKey="Donnellan P" first="Paul" last="Donnellan">Paul Donnellan</name><affiliation><nlm:affiliation>Galway University Hospital, Ireland; All-Ireland Oncology Research Group (ICORG), Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Oza, Amit" sort="Oza, Amit" uniqKey="Oza A" first="Amit" last="Oza">Amit Oza</name><affiliation><nlm:affiliation>Princess Margaret Hospital, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Avall Lundqvist, Elisabeth" sort="Avall Lundqvist, Elisabeth" uniqKey="Avall Lundqvist E" first="Elisabeth" last="Avall-Lundqvist">Elisabeth Avall-Lundqvist</name><affiliation><nlm:affiliation>Department of Oncology, Department of Clinical and Experimental Medicine, Linkoping, Sweden, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation></affiliation></author><author><name sortKey="Berek, Jonathan" sort="Berek, Jonathan" uniqKey="Berek J" first="Jonathan" last="Berek">Jonathan Berek</name><affiliation><nlm:affiliation>Stanford Women's Cancer Center, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hilpert, Felix" sort="Hilpert, Felix" uniqKey="Hilpert F" first="Felix" last="Hilpert">Felix Hilpert</name><affiliation><nlm:affiliation>Klinik fur Gynakologie und Geburtshilfe, UKSH, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ledermann, Jonathan A" sort="Ledermann, Jonathan A" uniqKey="Ledermann J" first="Jonathan A" last="Ledermann">Jonathan A. Ledermann</name><affiliation><nlm:affiliation>CRUK and UCL Cancer Trials Centre, NCRI UK, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Kaminsky, Marie Christine" sort="Kaminsky, Marie Christine" uniqKey="Kaminsky M" first="Marie Christine" last="Kaminsky">Marie Christine Kaminsky</name><affiliation><nlm:affiliation>ICL Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Stockler, Martin R" sort="Stockler, Martin R" uniqKey="Stockler M" first="Martin R" last="Stockler">Martin R. Stockler</name><affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="King, Madeleine T" sort="King, Madeleine T" uniqKey="King M" first="Madeleine T" last="King">Madeleine T. King</name><affiliation><nlm:affiliation>Psycho-oncology Research Group (PoCoG), School of Psychology, Central Clinical School, Sydney Medical School, University of Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation><nlm:affiliation>Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Prince of Wales Hospital, Sydney, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">29107348</PMID><DateCreated><Year>2017</Year><Month>11</Month><Day>06</Day></DateCreated><DateRevised><Year>2017</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Gynecologic oncology</Title><ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0090-8258(17)31422-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2017.10.019</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28. χ(2) tests for trend were used to examine the relationship between HRQL, PS and mGPS. Cox proportional hazards regression was used to assess associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Inflammatory markers were available in 516 of 948 patients in GCIG SBS. 200(39%) had potentially platinum sensitive ROC with ≥3 lines of chemotherapy, 316(61%) had platinum resistant ROC. 282(55%), 123(24%), 111(22%) had mGPS of 0, 1, 2, respectively. Median OS (months) was 18.1, 9.6, and 6.6 for mGPS 0, 1, and 2 respectively. mGPS was an independent predictor of OS after adjusting for PS and platinum sensitivity (p<0.001). mGPS remained a predictor of OS after adjusting for physical function, role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors (p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001). Higher mGPS was associated with worse HRQL, independent of PS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The mGPS is an independent predictor of OS in ROC after adjusting for HRQL and clinicopathological factors. Higher mGPS is associated with worse HRQL independent of PS. mGPS is simple, inexpensive and may be suitable for clinical practice, clinical trial patient selection and stratification.</AbstractText><CopyrightInformation>Crown Copyright © 2017. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roncolato</LastName><ForeName>Felicia T</ForeName><Initials>FT</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia. Electronic address: felicia.roncolato@ctc.usyd.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berton-Rigaud</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ICO Centre René Gauducheau, Saint Herblain, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanceley</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehouli</LastName><ForeName>Jalid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Charite Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buizen</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Aikou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jikei University School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aotani</LastName><ForeName>Eriko</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Kitasato Academic Research Organization, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorusso</LastName><ForeName>Domenica</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MITO, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnellan</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Ireland; All-Ireland Oncology Research Group (ICORG), Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oza</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Princess Margaret Hospital, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avall-Lundqvist</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Oncology, Department of Clinical and Experimental Medicine, Linkoping, Sweden, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berek</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford Women's Cancer Center, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilpert</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Klinik fur Gynakologie und Geburtshilfe, UKSH, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledermann</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>CRUK and UCL Cancer Trials Centre, NCRI UK, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminsky</LastName><ForeName>Marie Christine</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>ICL Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stockler</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Madeleine T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Psycho-oncology Research Group (PoCoG), School of Psychology, Central Clinical School, Sydney Medical School, University of Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Prince of Wales Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gynecol Oncol</MedlineTA><NlmUniqueID>0365304</NlmUniqueID><ISSNLinking>0090-8258</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Health related quality of life</Keyword><Keyword MajorTopicYN="N">Modified Glasgow Prognostic Score</Keyword><Keyword MajorTopicYN="N">Performance status</Keyword><Keyword MajorTopicYN="N">Prognostication</Keyword><Keyword MajorTopicYN="N">Recurrent ovarian cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29107348</ArticleId><ArticleId IdType="pii">S0090-8258(17)31422-1</ArticleId><ArticleId IdType="doi">10.1016/j.ygyno.2017.10.019</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000227 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000227 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:29107348
|texte= Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:29107348" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |